Publications

[25] Y Kai, et al. (2026). DISSECTING THE MOLECULAR BASIS OF POTENT HBF INDUCTION BY BMS-986470: A MECHANISTIC STUDY OF ZBTB7A/WIZ DUAL DEGRADATION. EHA Library. European Hematology Association Annual Congress 2026; Stockholm, Sweden.

[24] S Tamim, N Stong, Y Kai, D Jankeel, B Gaffney, A Kurtova, AR Perez, C Fontanillo, TT Chow, PR Hagner, D Jeyaraju, CC Bjorklund, M Amatangelo, K Wang, A Gandhi, M Ortiz-Estevez (2026). Development of a novel Ikaros/Aiolos transcriptional signature and correlation with patient response in multiple myeloma patients treated with CELMoDs. Cancer Research 86 (7 Suppl), Abstract nr 2714. AACR Annual Meeting 2026; San Diego, CA.

[23] Z Mo, L Groocock, S Wood, D Jankeel, D Mendy, ER Watson, Y Kai, et al. (2025). Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 For Diffuse Large B-Cell Lymphoma. Blood Cancer Discovery.

[22] Y Zhang*, S Zhou*, Yan Kai*, Y Zhang, C Peng, Z Li, MJ Mughal, B Julie, et al. (2024). O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer. Nature Communications 15 (1), 5597.

[21] T Liu, Q Zhu, Y Kai, T Bingham, S Wang, HJ Cha, S Mehta, TM Schlaeger, et al. (2024). Matrin3 mediates differentiation through stabilizing chromatin loop-domain interactions and YY1 mediated enhancer-promoter interactions. Nature Communications 15 (1), 1274.

[20] S Mehta, A Buyanbat, Y Kai, SH Orkin (2024). Mechanistic and kinetic insights into Transcription factor biology via acute protein depletion. Experimental Hematology, 104250.

[19] Yan Kai, N Liu, SH Orkin, GC Yuan (2023). Identifying Quantitatively Differential Chromosomal Compartmentalization Changes and Their Biological Significance from Hi-C data using DARIC. BMC Genomics.

[18] SN Olsen, L Godfrey, JP Healy, YA Choi, Y Kai, C Hatton, F Perner, et al. (2022). MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape. Molecular Cell 82 (6), 1140-1155.e11.

[16] T Harada, Y Heshmati, J Kalfon, MW Perez, JX Ferrucio, J Ewers, et al. (2022). A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia. Genes & Development 36 (5-6), 368-389.

[17] N Weng, J Kim, T Nguyen, J Cifello, R Ahmad, Y Zhang, Q Yang, JE Lee, et al. (2022). Lysine methyltransferase Kmt2d regulates naive CD8+ T cell activation-induced survival. Frontiers in Immunology 13, 8240.